XORTX Therapeutics Inc (XRTX) AI Stock Analysis

• Market Cap: C$3.90M
• Dividend Yield: N/A
• Average Volume (3M): 11.08K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.12
• Revenue Growth: N/A
• EPS Growth: -1939.32%
• Country: CA
• Employees: 2
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 6,962,218
• 10 Day Avg. Volume: 30,736
• 30 Day Avg. Volume: 11,079
• PEG Ratio: 0.02
• Price to Book (P/B): 1.28
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.94
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: C$0.47 ▼(-40.26% Downside)
• Action: Reiterated Date: 03/01/26
• Date: Action: Reiterated 03/01/26

The score is driven primarily by weak financial performance (no revenue, ongoing losses, and continued cash burn despite some improvement) and bearish technicals (below key moving averages with negative MACD). Valuation provides limited support due to negative earnings and no dividend.

Positive Factors

Focused kidney-disease pipeline (oxypurinol)

XORTX's concentrated R&D thesis around oxypurinol and kidney indications creates a focused development path and deep domain expertise. That concentration can reduce program management complexity, improve trial design consistency, and increase likelihood of executing near-term clinical milestones versus a scattered pipeline.

Low leverage / minimal debt

Minimal debt reduces near-term solvency and interest burdens, preserving financing optionality. With low leverage the company can prioritize equity or partnership financing for clinical programs, lowering default risk and maintaining strategic flexibility during multi-stage drug development timelines.

Improving cash outflows (reduced cash burn)

A materially reduced cash burn rate indicates better cost control or scaled-down spending, extending runway versus prior years. Sustained improvement in cash outflows can lower near-term financing frequency and gives management more time to advance clinical readouts or secure partnerships.

Negative Factors

No revenue; persistent operating losses

Absence of revenue and continued operating losses mean the business remains pre-revenue and unproven commercially. Long-term viability hinges entirely on clinical success or licensing; lack of internal revenue inflows increases dependence on outside capital and heightens dilution and execution risk over the medium term.

Ongoing cash burn; reliant on external financing

Persistent negative operating and free cash flow forces recurrent financing needs, which can dilute shareholders and shift strategic control. Dependence on external capital exposes programs to funding cycles and market conditions, potentially delaying trials or partnerships if financing terms tighten.

Material erosion of equity base

Steady equity erosion reduces the company's buffer to absorb losses and constrains balance-sheet capacity to support development programs. A much smaller equity base weakens negotiating leverage with partners or lenders and increases vulnerability to adverse funding conditions during multi-year clinical development.

XORTX Therapeutics Inc Business Overview & Revenue Model

Company Description

XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.

How the Company Makes Money

XORTX Therapeutics Inc primarily generates revenue through the development and potential commercialization of its proprietary drug therapies. The company seeks to advance its lead product candidates through clinical trials, with the ultimate goal of obtaining regulatory approval for marketing and sales. Revenue streams are expected to come from licensing agreements, partnerships with larger pharmaceutical companies, and potential milestone and royalty payments based on the successful development and commercialization of its therapies. As a clinical-stage company, XORTX may also rely on funding through public or private investments to support its research and development activities until its products reach the market.

XORTX Therapeutics Inc Financial Statement Overview

Summary

Financials reflect an early-stage biotech with no revenue, ongoing operating/net losses, and continued negative operating and free cash flow. Losses and cash burn have moderated versus 2022, and leverage is minimal, but the sharp erosion in equity and lack of self-funding keep overall financial strength weak.

Income Statement

The income statement remains very weak: the company reports no revenue across the period provided and continues to generate operating losses and net losses. Losses have narrowed versus 2022 (net loss improved from about -$12.4M at the operating level in 2022 to about -$4.5M in 2025), but profitability is still firmly negative and the business has not yet demonstrated a revenue base to absorb costs.

Balance Sheet

Leverage is low, with debt staying minimal (debt-to-equity roughly ~0.0–0.02), which reduces solvency risk. However, the equity base has declined materially (from ~$13.2M in 2021 to ~$2.9M in 2025) and returns on equity are deeply negative, reflecting ongoing losses and balance sheet erosion.

Cash Flow

Cash burn remains significant, with operating cash flow and free cash flow negative each year. A positive sign is that cash outflows have generally moderated from 2022–2023 to 2024–2025 (free cash flow improving from roughly -$9.0M in 2022 to about -$3.9M in 2025), but the company is still not self-funding and will likely depend on external financing until revenues or meaningful cost reductions emerge.

Breakdown	Dec 2025	Dec 2024	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-156.66K	-160.66K	―	-75.27K	-17.88K
EBITDA	-4.39M	-4.38M	―	-9.41M	―
Net Income	-3.71M	-4.54M	―	―	-1.65M
Balance Sheet
Total Assets	3.68M	5.89M	5.47M	12.37M	17.38M
Cash, Cash Equivalents and Short-Term Investments	1.19M	3.56M	3.45M	10.43M	14.79M
Total Debt	51.11K	55.78K	11.51K	77.60K	0.00
Total Liabilities	821.18K	1.09M	825.94K	5.38M	4.18M
Stockholders Equity	2.86M	4.80M	4.64M	7.00M	13.20M
Cash Flow
Free Cash Flow	-3.87M	-5.04M	-6.63M	-9.01M	-4.83M
Operating Cash Flow	-3.87M	-5.04M	-6.58M	-8.96M	-4.80M
Investing Cash Flow	-412.13K	-53.32K	-46.36K	-45.70K	-31.81K
Financing Cash Flow	1.99M	3.81M	-487.30K	4.71M	19.37M

XORTX Therapeutics Inc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.78
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:XRTX, the sentiment is Negative. The current price of 0.78 is above the 20-day moving average (MA) of 0.56, above the 50-day MA of 0.70, and below the 200-day MA of 1.00, indicating a bearish trend. The MACD of -0.06 indicates Negative momentum. The RSI at 34.29 is Neutral, neither overbought nor oversold. The STOCH value of 31.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:XRTX.

XORTX Therapeutics Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
APS	51 Neutral	C$5.59M	-0.19	―	―	―	90.81%
MOOD	47 Neutral	C$4.33M	-4.14	-41.36%	―	-50.89%	-32.33%
XRTX	42 Neutral	C$3.90M	-0.67	-96.61%	―	―	-1939.32%
KNE	41 Neutral	C$6.36M	-2.87	―	―	―	―
BIOV	29 Underperform	C$3.79M	-0.58	―	―	―	25.09%

XORTX Therapeutics Inc Corporate Events

XORTX Leans Into Genetic Breakthroughs in Gout as It Reshapes Board and Advances Oxypurinol

XORTX Therapeutics highlighted newly published, large-scale genetic research showing that hundreds of genetic factors are implicated in urate biology and gout, reinforcing the central role of xanthine oxidase over-expression in hyperuricemia, gout, polycystic kidney disease and related kidney and metabolic conditions. Management framed these findings as validation of its XO-inhibition strategy and precision medicine focus, noting that its planned clinical trial of oxypurinol is a key step toward a future new drug application and could strengthen the company’s positioning in treating both diabetic and non-diabetic kidney diseases. In a corporate update, XORTX announced the appointment of veteran biotech strategist Krysta Davies Foss to its board and the resignation of three directors, moves that streamline the board and add commercialization and market-preparedness expertise as the company advances its clinical and partnering agenda.

The most recent analyst rating on (TSE:XRTX) stock is a Hold with a C$0.81 price target. To see the full list of analyst forecasts on XORTX Therapeutics Inc stock, see the TSE:XRTX Stock Forecast page.